Authors: E. Češková Authors‘ workplace: Psychiatrická klinika LF MU a FN Brno, přednosta prof. MUDr. E. Češková, CSc. Published in: Čes. a slov. Psychiat., , 2001, No. 8, pp. 418-421. Category:
Risperidone is the first atypical antipsychotic registered as adjuvant treatment in bipolar disorder. The theoretical and practical reasons for this indication are summarized. Individual studieswith bipolar disorders demonstrating the justification for this indication are presented. Czechexperience is also included. Open, mostly short-term studies with risperidone in bipolar disorders, long-term open study and double-blind studies where risperidone was administered in indications mentioned as monotherapy and in combination with mood stabilizers are reviewed indetail.
Key words: risperidone, bipolar disorder, mood stabilizers, manic symptomatology.
Don‘t have an account? Create new account
Enter the email address that you registered with. We will send you instructions on how to set a new password.
